Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $11.01B | +6.2% | $1.65B | $4.43 | +11.3% | 40.3% | 17.4% |
| Q4 2025 Dec 2025 | $12.22B | +7.2% | $1.96B | $5.21 | — | 41.0% | 18.9% |
| Q3 2025 Sep 2025 | $11.12B | — | $1.62B | $4.27 | — | 41.2% | 18.7% |
| Q2 2025 Jun 2025 | $10.85B | — | $1.62B | $4.28 | — | 40.6% | 17.7% |
| Q1 2025 Mar 2025 | $10.36B | — | $1.51B | $3.98 | — | 40.9% | 17.5% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can upbeat Thermo Fisher earnings and a higher 2026 outlook really justify a double-digit stock plunge on weak organic growth?